Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders : Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Unrelated Donor for the Treatment of Hematological Diseases
This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF)..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
ClinicalTrials.gov - (2024) vom: 16. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: October 19, 2017, Last downloaded: ClinicalTrials.gov processed this data on April 24, 2024, Last updated: April 24, 2024 |
|---|
| Study ID: |
NCT03314974 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG002567741 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG002567741 | ||
| 003 | DE-627 | ||
| 005 | 20240424010529.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210408s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG002567741 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT03314974 | ||
| 035 | |a (UBBS_Klinische_Studien)2015LS034 | ||
| 035 | |a (UBBS_Klinische_Studien)MT2015-29 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders |b Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Unrelated Donor for the Treatment of Hematological Diseases |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: October 19, 2017, Last downloaded: ClinicalTrials.gov processed this data on April 24, 2024, Last updated: April 24, 2024 | ||
| 520 | |a This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF). | ||
| 650 | 2 | |a Burkitt Lymphoma | |
| 650 | 2 | |a Lymphoma | |
| 650 | 2 | |a Leukemia | |
| 650 | 2 | |a Multiple Myeloma | |
| 650 | 2 | |a Lymphoma, Non-Hodgkin | |
| 650 | 2 | |a Precursor Cell Lymphoblastic Leukemia-Lymphoma | |
| 650 | 2 | |a Leukemia, Lymphocytic, Chronic, B-Cell | |
| 650 | 2 | |a Leukemia, Myeloid | |
| 650 | 2 | |a Lymphoma, Mantle-Cell | |
| 650 | 2 | |a Leukemia, Myelogenous, Chronic, BCR-ABL Positive | |
| 650 | 2 | |a Lymphoma, B-Cell, Marginal Zone | |
| 650 | 2 | |a Leukemia, Prolymphocytic | |
| 650 | 2 | |a Leukemia, Myelomonocytic, Juvenile | |
| 650 | 2 | |a Waldenstrom Macroglobulinemia | |
| 650 | 2 | |a Leukemia, Plasma Cell | |
| 650 | 2 | |a Anemia | |
| 650 | 2 | |a Myeloproliferative Disorders | |
| 650 | 2 | |a Anemia, Refractory | |
| 650 | 2 | |a Bone Marrow Failure Disorders | |
| 650 | 2 | |a Pancytopenia | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Recruiting | |
| 650 | 4 | |a Phase: Phase 2 | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2024) vom: 16. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:16 |g month:04 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT03314974 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 16 |c 04 | ||